To listen to the webcast, click here.
In a unanimous decision on June 13, 2013, the U.S. Supreme Court ruled that isolated, naturally occurring human gene sequences are a product of nature and thus not patent-eligible subject matter. The Court did, however, hold that synthetically created DNA (cDNA) is patent-eligible because it is not naturally occurring.
As the biotechnology industry digests the Myriad decision and assesses its impact on patent portfolios, this program will discuss the significant effects that the decision will have on the future of patents to inventions derived from naturally occurring substances and the important questions you may want to consider.
Topics Will Include: